Revenue distribution by sectors:

1. Blood plasma products: approx. 70%
2. Biopharmaceutical products: approx. 20%
3. Other medical products and services: approx. 10%

TOP 3 markets and their percentage shares:

1. China: approx. 60%
2. USA: approx. 25%
3. Europe: approx. 10%

Shanghai RAAS Blood Products Co., Ltd. generates the majority of its revenue from the manufacturing and distribution of blood plasma products. These products are essential for treating patients with coagulation disorders and other medical conditions.

The Chinese market is the company's largest sales market, attributed to high demand and a large population share. The USA and Europe follow as important markets, with the USA having a larger share than Europe due to advanced medical infrastructure and high demand for biopharmaceutical products.

Production Sites: Mainly in China

Shanghai RAAS Blood Products Co., Ltd. primarily produces its products in China. The company operates multiple production facilities in the country that specialize in the manufacturing of blood products. These sites are strategically located in various regions of China to ensure efficient supply and distribution.

Shanghai RAAS is known for its comprehensive infrastructure in the blood plasma industry, which enables the company to take a leading position in the Chinese market.

Revenue Growth: Estimated 8-10% annually (2025 forecast)

Shanghai RAAS Blood Products Co., Ltd. pursues a growth strategy based on several core areas. Firstly, the company focuses on expanding its product range through research and development of new blood products and therapies. This is intended not only to increase market share in existing markets but also to enable entry into new markets.

Secondly, Shanghai RAAS is investing in strategic partnerships and acquisitions to strengthen its global presence. This strategy aims to leverage synergies and gain access to new technologies and markets.

Finally, the company places great emphasis on improving efficiency in production and logistics to reduce costs and enhance margins. This is achieved through the use of advanced technologies and automation.

Through these measures, the company expects to enhance its competitiveness and achieve sustainable growth.

Commodities/Materials: Blood plasma, chemical reagents

Main importing countries: USA, Europe (especially Germany and Austria)

Shanghai RAAS Blood Products Co., Ltd. is a leading company in the blood products industry and mainly imports blood plasma, which serves as an essential raw material for the production of blood products. The USA is a significant supplier of blood plasma due to its well-developed infrastructure for plasma donations.

In addition, the company imports chemical reagents and other specialized materials necessary for the processing and refinement of blood products. These materials often come from European countries, especially from Germany and Austria, known for their high-quality pharmaceutical products.

Shanghai RAAS's import strategy aims to secure the best available raw materials to ensure the quality and effectiveness of their products.

Market share in China: approximately 20% (2024, estimate)
Research and development investments: 5% of revenue (2023)
Industry growth: 8% annually (2023)

Shanghai RAAS Blood Products Co., Ltd. has a significant competitive advantage in the blood products industry in China, mainly due to its high market share and established supply chains. The company benefits from strong brand recognition and a wide product portfolio, allowing it to meet diverse customer needs.

Another advantage is the continuous investment in research and development, which accounts for about 5% of revenue. These investments support the development of new products and the enhancement of existing technologies, which are crucial for maintaining competitiveness.

The company operates in a market that grows annually by approximately 8%, providing additional opportunities for expansion and revenue growth. Despite intense competition in the industry, Shanghai RAAS remains well positioned to benefit from this growth through its strategic alliances and partnerships.

Institutional Investor Share: approximately 25% (estimated for 2025)

Insider Purchases/Sales: No significant transactions in the last 12 months (estimated for 2025)

The institutional investor share in Shanghai RAAS Blood Products Co., Ltd. is estimated to be around 25%. This indicates that a significant portion of the shares are held by institutional investors, suggesting a certain level of confidence in the company's long-term stability and growth potential.

Regarding insider purchases or sales, there have been no significant transactions in the last 12 months. This could indicate that the management and other insiders are satisfied with the current valuation of the company or do not expect any significant changes in the company's strategy or performance.

Market share of Shanghai RAAS Blood Products Co., Ltd.: 12% (estimated, 2025)

Top competitors and their market shares:

1. CSL Limited: 20%
2. Grifols, S.A.: 18%
3. Takeda Pharmaceutical Company Limited: 15%
4. Shanghai RAAS Blood Products Co., Ltd.: 12%
5. Kedrion Biopharma: 10%
6. Octapharma AG: 8%
7. BPL (Bio Products Laboratory): 7%
8. Sanquin: 5%
9. LFB Group: 3%
10. Biotest AG: 2%

Shanghai RAAS Blood Products Co., Ltd. is a significant player in the field of blood products, especially in China. The market share of approximately 12% indicates a strong position, albeit behind global leaders like CSL Limited and Grifols, which have larger resources and a broader international presence.

Shanghai RAAS's moat is primarily based on its strong position in the Chinese market, where it benefits from regulatory advantages and high market demand. However, compared to global competitors, its moat is less pronounced as these companies have a broader product portfolio and stronger global presence.

A significant advantage of Shanghai RAAS could be its local market knowledge and ability to quickly respond to regulatory changes in China. However, larger international companies often have better research and development resources and stronger brand recognition worldwide, giving them a potential edge.

Revenue Growth: 10.5% (2024) Profit Growth: 8.2% (2024) Market Share in the Blood Products Sector in China: 15% (2024)

Shanghai RAAS Blood Products Co., Ltd. recorded a solid revenue growth of 10.5% in 2024, attributed to increasing demand for blood products and an effective market strategy. The company was able to increase its profit by 8.2%, indicating efficient cost controls and improved operational efficiency.

The 15% market share in the Chinese blood products sector indicates that Shanghai RAAS has a strong position in a rapidly growing market. Demographic trends and increasing healthcare services in China continue to offer growth opportunities.

Additionally, the company is investing in research and development to develop innovative products, which could strengthen its competitiveness in the long term. These factors suggest that Shanghai RAAS could be a promising investment, especially for investors interested in long-term growth.

Dividend Yield: 1.8% (2024)

Shanghai RAAS Blood Products Co., Ltd. distributed a dividend yield of 1.8% in 2024. The company is known for its stable dividend policy, having regularly paid dividends to its shareholders in recent years.

The reliability of the distribution can be considered relatively high, as the company operates in a stable industry and has a solid financial foundation. However, investors should regularly review the financial situation and market conditions to identify potential risks.